Adaptive Biotechnologies Signs Two Immune Receptor Licensing Agreements with Pfizer
I'm PortAI, I can summarize articles.
Adaptive Biotechnologies Corporation has signed two non-exclusive agreements with Pfizer Inc. The first agreement involves identifying disease-specific T-cell receptors in rheumatoid arthritis, with Pfizer handling development and commercialization. Adaptive will receive up to $890 million in payments. The second agreement grants Pfizer access to Adaptive’s TCR-antigen datasets for AI and machine learning research. Adaptive will receive upfront and potential annual licensing fees. Financial terms for the data licensing were not disclosed.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments